Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR4195653

—

46f012a5-3c80-5100-ae0b-661da3b6978d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.660
  • E2F_TARGETS+0.630
  • G2M_CHECKPOINT+0.570
  • UNFOLDED_PROTEIN_RESPONSE+0.500
  • MTORC1_SIGNALING+0.470
  • MYC_TARGETS_V2+0.460
  • PROTEIN_SECRETION+0.440
  • OXIDATIVE_PHOSPHORYLATION+0.370
  • DNA_REPAIR+0.340
  • MITOTIC_SPINDLE+0.310

Top 10 suppressed

  • BILE_ACID_METABOLISM-0.360
  • NOTCH_SIGNALING-0.290
  • KRAS_SIGNALING_DN-0.280
  • INTERFERON_GAMMA_RESPONSE-0.270
  • INTERFERON_ALPHA_RESPONSE-0.240
  • MYOGENESIS-0.210
  • XENOBIOTIC_METABOLISM-0.200
  • IL6_JAK_STAT3_SIGNALING-0.190
  • HEDGEHOG_SIGNALING-0.180
  • INFLAMMATORY_RESPONSE-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-21-1072-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.895
2SRR6013564
lung-landscapes@6
—cohortSQ20.871
3SRR934938
brain-umap@2
——0.855
4MNG732
mng-umap@100
——0.853
5BS_8ZS9F31R
brain-umap@2
high-grade glioma—0.853
667719D37-8CC2-42B5-AF44-6D5AC258FDB1
brain-umap@2
——0.853
7MDT-AP-0322
medullo-epn-umap@date-based
MedMedulloblastoma0.852
8MDT-AP-0359
medullo-epn-umap@date-based
MedMedulloblastoma0.850
9TCGA-56-7222-01A-11R-2045-07
lung-landscapes@6
—cohortSQ10.848
10ULC0595T_S33
lung-landscapes@6
—cohortA10.848

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.660Inavolisib— uncovered
E2F_TARGETS0.630Inavolisib— uncovered
G2M_CHECKPOINT0.570Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.500Idelalisib— uncovered
MTORC1_SIGNALING0.470Inavolisib— uncovered
MYC_TARGETS_V20.460Idelalisib— uncovered
PROTEIN_SECRETION0.440Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.370Remibrutinib— uncovered
DNA_REPAIR0.340Idelalisib— uncovered
MITOTIC_SPINDLE0.310Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.290Inavolisib— uncovered
GLYCOLYSIS0.270Inavolisib— uncovered
HYPOXIA0.210Idelalisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
APOPTOSIS0.190Idelalisib— uncovered
TGF_BETA_SIGNALING0.190Inavolisib— uncovered
ANGIOGENESIS0.180Remibrutinib— uncovered
SPERMATOGENESIS0.170Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.150Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.130Idelalisib— uncovered